Education
About Us
Working with TipRanks
Follow Us
Nymox Pharmaceutical (NYMXF)
OTHER OTC:NYMXF
Total Valuation
Nymox Pharmaceutical has a market cap or net worth of $3.79M. The enterprise value is $3.71M.
Market Cap$3.79M
Enterprise Value$3.71M
Share Statistics
Nymox Pharmaceutical has 94,540,140 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding94,540,140
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Nymox Pharmaceutical’s return on equity (ROE) is 0.66 and return on invested capital (ROIC) is 63.22%.
Return on Equity (ROE)0.66
Return on Assets (ROA)-6.87
Return on Invested Capital (ROIC)63.22%
Return on Capital Employed (ROCE)0.63
Revenue Per Employee0.00
Profits Per Employee-1.50M
Employee Count3
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Nymox Pharmaceutical is ―. Nymox Pharmaceutical’s PEG ratio is 0.04.
PE Ratio―
PS Ratio0.00
PB Ratio-1.38
Price to Fair Value-1.38
Price to FCF-3.60
Price to Operating Cash Flow-5.26
PEG Ratio0.04
Income Statement
In the last 12 months, Nymox Pharmaceutical had revenue of 0.00 and earned -4.49M in profits. Earnings per share was -0.05.
Revenue0.00
Gross Profit-1.00K
Operating Income-4.28M
Pretax Income-4.49M
Net Income-4.49M
EBITDA-4.26M
Earnings Per Share (EPS)-0.05
Cash Flow
In the last 12 months, operating cash flow was -717.00K and capital expenditures 0.00, giving a free cash flow of -717.00K billion.
Operating Cash Flow-717.00K
Free Cash Flow-717.00K
Free Cash Flow per Share>-0.01
Dividends & Yields
Nymox Pharmaceutical pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-391.53
52-Week Price Change-55.56%
50-Day Moving Average0.05
200-Day Moving Average0.07
Relative Strength Index (RSI)44.75
Average Volume (3m)21.72K
Important Dates
Nymox Pharmaceutical upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Nymox Pharmaceutical as a current ratio of 0.09, with Debt / Equity ratio of 0.00%
Current Ratio0.09
Quick Ratio0.09
Debt to Market Cap0.00
Net Debt to EBITDA0.02
Interest Coverage Ratio-18.95
Taxes
In the past 12 months, Nymox Pharmaceutical has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Nymox Pharmaceutical EV to EBITDA ratio is -2.18, with an EV/FCF ratio of -3.57.
EV to Sales0.00
EV to EBITDA-2.18
EV to Free Cash Flow-3.57
EV to Operating Cash Flow-3.57
Balance Sheet
Nymox Pharmaceutical has $74.00K in cash and marketable securities with $0.00 in debt, giving a net cash position of $74.00K billion.
Cash & Marketable Securities$74.00K
Total Debt$0.00
Net Cash$74.00K
Net Cash Per Share<$0.01
Tangible Book Value Per Share-$0.07
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Nymox Pharmaceutical is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―